INVENTISBIO CO., LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.4 CNY | +0.11% |
|
-5.34% | -37.91% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.4
CNY
Average target price
18.5
CNY
Spread / Average Target
+96.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.91% | 750M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- 688382 Stock
- News InventisBio Co., Limited
- InventisBio, Beida Pharmaceutical Get Registration Certification for Befortinib Mesylate Capsules
